AstraZeneca seeks emergency use authorization of covid prophylaxis drug in U.S

On Tuesday, drugmaker AstraZeneca announced that it has requested an emergency use authorization grant from the U.S. Food and Drug Administration (FDA) for its Covid-19 prophylaxis drug.

This comes a month after the antibody cocktail was proven to be effective in the prevention of Covid symptoms among people highly at risk to be infected who received the drug prior to exposure, according to Forbes.

According to the company in a press release, its Phase III trial featuring over 5,000 participants revealed that the antibody cocktail was 77% effective in people who received the drug as a preventive measure by reducing the risk of developing Covid-19 symptoms.

Related posts

Australia to buy 300,000 Merck’s Covid-19 capsule as cases hit record high

WHO: Air pollution increases risk of severe COVID-19 infection

The drug was developed as an antibody treatment that uses lab-made antibodies that can stay for months in the recipient’s body and protect them against infection.

It is however, important to note that the antibody treatments are not vaccines. Unlike the antibody treatments, vaccine which helps a recipient’s immune system build its own antibodies and infection-fighting cells against the virus.

According to Astrazeneca, the antibody treatment is effective in protecting people who may not develop a robust immune response to Covid-19 vaccines.

In addition, the company noted that trials performed in Vitro, I.e test tubes showed that the drug was able to neutralize emergent Covid variants, including delta and mu, adding that supply agreements for the antibody cocktail are in the works with the United States and other governments.

As stated by Astrazeneca’s chief of research and development, Mene Pangalos: “Vulnerable populations such as the immunocompromised often aren’t able to mount a protective response following vaccination and continue to be at risk of developing COVID-19. With this first global regulatory filing, we are one step closer to providing an additional option to help protect against COVID-19 alongside vaccines.”

Recall that, in June 2021, a trial of AstraZeneca’s antibody therapy among patients exposed to the virus failed to prevent symptoms. The effectiveness of the drug among people already exposed to the virus was only 33%, including exposed individuals who tested negative.

Related

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
Pogoda na jutro. Deszcz i deszcz ze śniegiem, silniejszy wiatr thumbnail

Pogoda na jutro. Deszcz i deszcz ze śniegiem, silniejszy wiatr

Pogoda na jutro, piątek 25.02, przyniesie opady deszczu i deszczu ze śniegiem. Na termometrach zobaczymy do ośmiu stopni Celsjusza. Miejscami powieje silniejszy wiatr z porywami do 60 kilometrów na godzinę.W ciągu nadchodzącej doby nasz kraj dostanie się pod wpływ niżu znad Skandynawii - nad Polską ponownie pojawią się fronty atmosferyczne. Przyniosą przede wszystkim opady deszczu,…
Read More
Brazil sets record for beef exports despite China's embargo thumbnail

Brazil sets record for beef exports despite China's embargo

O Brasil exportou 187 mil toneladas de carne bovina em setembro, maior volume já embarcado em um mês, mostraram dados da Secex (Secretaria de Comércio Exterior) hoje (1), em meio a incertezas com lotes enviados à China apesar de uma suspensão temporária de compras pelo país asiático. Principal destino da carne brasileira, a China suspendeu…
Read More
Dewan Negara passes Cyber Security Bill 2024 thumbnail

Dewan Negara passes Cyber Security Bill 2024

KUALA LUMPUR: The Dewan Negara today passed the Cyber Security Bill 2024. The bill was unanimously passed after the third reading by Digital Minister Gobind Singh Deo (pix). The aim of the bill is to enhance the nation’s cyber security through compliance with specific measures, standards, and processes in managing cyber security threats. Earlier, Gobind
Read More
Record year for exports of Norwegian seafood thumbnail

Record year for exports of Norwegian seafood

2021 ble et rekordår for eksport av norsk sjømat. Norge eksporterte i fjor 3,1 millioner tonn sjømat til en verdi av over 120 milliarder kroner. 1 min Publisert: 05.01.22 — 06.23 Oppdatert: 2 timer siden Det er ny rekord både i volum og verdi, opplyser Norges sjømatråd i en pressemelding. Den totale eksporten på 3,1…
Read More
Korea to Join Early Meeting of U.S.-Led Chip Alliance thumbnail

Korea to Join Early Meeting of U.S.-Led Chip Alliance

Korean officials will attend a preliminary meeting of the U.S.-led Chip 4 alliance, a semiconductor coalition that also includes Japan and Taiwan to reduce global dependence on China. But Seoul wants to scupper a clause in the draft rules that would ban exports to China. A presidential office source said Sunday, "We expect to continue to…
Read More
Index Of News
Total
0
Share